Featured Success Stories
SIU School of Medicine strongly supports the development and formation of new business ventures that might spawn out from intellectual property successes. Several faculty members have already actively engaged with the Office of Technology Transfer and have made significant contributions to the University and the community.
Dr. Brewer is one outstanding example of an innovation success story that has made an impact on the benefit for the public good. His research has produced a novel means of storing brain tissue for up to one month with refrigeration and standard pressure (see PubMed). This novel solution makes handling, storing and testing brain tissue much easier than what has previously been used. With Dr. Brewer’s intellectual property protection, he founded BrainBits, LLC, a medical supply company based in Springfield, IL that ships BrainBits™ and Hibernate™ media for research purposes. He is now looking for interest in preclinical studies for using this technology for faster recovery from brain surgery, spinal cord injury, head trauma and brain cancer. Dr. Brewer has an issued patent, as well as several trade secrets. Information on the issued patent related to his discovery can be found with the following link.
Cultural Medium for Maintaining Neural Cells in Ambient Atmosphere, US Patent # 6,180,404
Dr. Campbell is another outstanding example of tireless efforts in advancing potential drugs to market by engaging outside entities and partners such as Molecular Therapeutics, Inc., the Department of Defense, and other supportive agencies. Dr. Campbell has developed therapeutic uses for D-Methionine to reduce the toxicity of platinum-containing anti-tumor compounds, ototoxic drugs, noise and radiation. She continues to develop and refine treatment and prevention applications for D-Methionine and similar compounds while working on other products that can improve hearing loss.
Dr. Campbell’s research has always been focused on improving patient care, which is a direct result of being a full-time clinician for 12 years. Dr. Campbell believed that the key to bringing her drug to market was through patent prosecution. Dr. Campbell states, “I knew that unless I obtained patents, no one would ever invest the millions required to take my new drug therapies through FDA approved clinical trials. Thus the only way my research would ever really help patients was to obtain the drug patents, get the patents licensed and through clinical trials, and hopefully have a new FDA approved drug therapy for patients in the future. Through this process I can potentially improve patient care in many thousands of patients every year, far more than I ever could in my clinical practice.” Dr. Campbell has several issued patents and pending patent applications on her discoveries that can be found with the following links.
Therapeutic Use of D-Methionine to Reduce the Toxicity of Platinum-Containing Anti-Tumor Compounds, US Patent #6,187,817
Therapeutic Use of D-Methionine to Reduce the Toxicity of Ototoxic Drugs, Noise, and Radiation, US Patent #6,265,386
Therapeutic Use of D-Methionine to Reduce the Toxicity of Noise, US Patent #7,071,230.
Therapeutic Use of Methionine-Derivatives to Reduce the Toxicity of Noise, US Patent #7,423,065.
Therapeutic Use of Methionine to Reduce the Toxicity of Platinum-Containing Anti-Tumor Compounds, US Patent #7,557,142.
Therapeutic Use of Methionine for the Treatment or Prevention of Mucositis, foreign applications pending.